Last reviewed · How we verify
NCT03747991
How Reflux Medications Affect the Microbiome of Infants
trial in GERD in 12 participants. Completed in 31 July 2019.
30 April 2019
Quick facts
| Lead sponsor | Nemours Children's Clinic |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 12 |
| Start date | 13 August 2018 |
| Primary completion | 30 April 2019 |
| Estimated completion | 31 July 2019 |
| Sites | 1 location across United States |
Conditions studied
Sponsor
Nemours Children's Clinic
Who can join
Adults 2 Months to 12 Months, any sex, with GERD or Dysbiosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The changes in the organisms making up the gut microbiota in infants who are taking anti-acid reflux medications (histamine 2 receptor antagonists) as compared to infants who are not taking these medications is not well-studied or understood. Whether these medications change the gut microbiota and microbiome, and what that change may imply for children on these medications, is the focus of this study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03747991
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for GERD
Currently open trials in the same condition.
- NCT06953986 — A Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA · NA · recruiting
- NCT07421011 — Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 · Phase 1 · recruiting
- NCT07268820 — Heartburn, Gastroesophageal Reflux Disease · Phase 4 · recruiting
- NCT06955520 — Vonaprazan Versus Esomeprazole for Healing of LA Grade B or Higher Esophagitis After POEM · NA · recruiting
- NCT06641375 — Anti-Reflux Endoscopic Therapy Using Argon Plasma Coagulation (AREA) in Gastroesophageal Reflux Disease (GERD) Patients: · NA · recruiting
Other Nemours Children's Clinic trials
Trials by the same sponsor.
- NCT06616818 — DASH Diet Intervention for Systemic Hypertension in Adolescents · NA · withdrawn
- NCT07218588 — Sanctuary Farm Prescription in Adolescents · NA · recruiting
- NCT06406621 — Pilot Trial Assessing the Effectiveness of Laser Hair Depilation on Pilonidal Disease Recurrence in Patients With Darker · NA · recruiting
- NCT07154667 — Evaluation of the Auryzon™ EAR 2.0 System in Ear Reconstruction · NA · recruiting
- NCT07212049 — Ultrasound Use to Measure Magnetically Controlled Growing Rods · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03747991 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nemours Children's Clinic
- Last refreshed: 12 June 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03747991.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing